GenSight Biologics Shareholders Approve Majority of Board's Resolutions

On May 13, 2025, GenSight Biologics held its Combined General Meeting in Paris, where most resolutions recommended by the Board were approved. The quorum achieved stood at 56.51%. Notably, Resolution A was the sole proposal not adopted. CEO Laurence Rodriguez highlighted the achievements of 2024, which included improved financial structuring and manufacturing advancements.

Financially, new investors joined, and existing shareholders reinforced their support. Manufacturing progress was evident through technology optimization and the successful release of active substance batches. Moving forward, priorities for 2025 include finalizing the Phase III RECOVER protocol and submitting the LUMEVOQ® dossier to UK's MHRA. GenSight remains focused on cost discipline and strategic partnerships.